Table 1.
Study and patient characteristics overview.
| Study Design | Number of Patients | Number of Patients with Paired Pre- and Post-NACT | Histotype | Site of Origin | TILs Assessment | Type of CHT | Number of Cycles | FU | |
|---|---|---|---|---|---|---|---|---|---|
| Polcher et al. 2010 [23] |
Prospective | 93 | 30 | Serous/serous-papillary High-grade endometrioid (EC) |
Intraperitoneal biopsies | Hematoxylin staining (HS) Immunohistochemistry (IHC) |
Platinum-/ taxane-based NAC |
3 cycles | 24 months |
| Bohm et al. 2016 [24] |
Prospective | 60 | 54 | HGSC | Omental biopsies and plasma samples | IHC, flow cytometry (FC), electrochemiluminescence assays, and RNA sequencing (RS) |
Taxane/platinum combinations | 3 or >4 | NA |
| Lo et al. 2016 [25] |
Retrospective | 150 | 26 (in 18 patients, paired anatomic extra-pelvic biopsies were available) |
HGSC | Omentum, pelvic site, uterus, colon, abdomen, cul-de-sac (paired only extra-pelvic biopsies) |
IHC (Aperio, Pannoramic MIDI, Vectra) |
Platinum-/ taxane-based NAC |
A mean of 4 cycles | NA |
| Mesnage et al. 2016 [26] |
Retrospective | 150 | 83 | High-grade serous (HGSC), EC, clear cell (CC), low-grade serous (LGSC), mucinous carcinoma (MC) |
NA | Hematoxylin and eosin staining (HES) IHC |
Carboplatin and paclitaxel | Average 4 cycles | 52 months |
| Kim et al. 2018 [27] |
Retrospective | 266 | 76 | HGSC | Omental biopsies | HES, IHC (Ventana XT automated stainer) | Taxane/platinum combinations | A median of 3 cycles (range, 2–6 cycles) |
Median: 30 months |
| Chen et al. 2020 [28] |
Retrospective | 189 | 15 | HGSC, CC, EC, MC | NA | HES, IHC (Aperio ScanScope AT Turbo scanner) | Platinum-based treatment | N/A | 37 months |
| Leary et al. 2020 [29] |
Retrospective | 150 | 53 | HGSC, EC, CC, other high-grade, LGSC, MC |
NA | HES, IHC | Platinum and paclitaxel | Mean number of cycles: 4 | Median: 80 months |
| Félix Blanc-Durand et al. 2020 [30] |
Retrospective | 98 | 63 | HGSC, LGSC, mixed, poorly differentiated, EC, CC, MC | NA | HES, IHC (Ventana XT automated stainer) | Platinum-based treatment | N/A | N/A |
| Lee et al. 2022 [31] |
Retrospective | 147 | 147 | HGSC | NA | HES, IHC (Ventana XT automated stainer), whole-transcriptome sequencing (WTS) |
Platinum-based chemotherapy | Median of 3 cycles (range, 3–4 cycles) |
Median: 28.2 months |